drugset / Trial / NCT00000233
Alternate Day Buprenorphine Administration, Phase X - 15
Treatment
Summary
The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.
Timeline
- Start
- 1993-05
- Primary completion
- —
- Completion
- —
Publications
- Background Petry, Bickel (in press) Buprenorphine self-administration in buprenorphine-maintained, opioid-dependent outpatients: Effects of an alternate reinforcer. Psychopharmacology. Petry, Bickel (in press) Buprenorphine self-administration in buprenorphine-maintained, opioid-dependent outpatients: Effects of an alternate reinforcer. Psychopharmacology
- Antoniotti C, Germani MM, Rossini D, Lonardi S, Pietrantonio F, Santini D, Marmorino F, Allegrini G, Daniel F, Raimondi A, Borelli B, Zaniboni A, Conca V, Abraham J, Spetzler D, Maiello E, Boccaccino A, Passardi A, Giordano M, Tamburini E, Korn MW, Masi G, Cremolini C. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. Eur J Cancer. 2022 May;167:23-31. doi: 10.1016/j.ejca.2022.02.031. Epub 2022 Mar 30.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | — | — |